Please login to the form below

Not currently logged in
Email:
Password:

CureVac appoints chief financial officer

Pierre Kemula joins the mRNA company’s management board

CureVac Pierre KemulaTübingen, Germany-based mRNA firm CureVac has appointed Pierre Kemula as its new chief financial officer.

Kemula will have responsibility for managing CureVac's financial and capital markets activities and joins the company's management board.

Previously, Kemula served as chief financial officer of Pixium Vision, a medical technology company specialising in the development of technologies for patients with outer retinal degeneration.

He also brings experience from Ipsen, where he was vice president of corporate finance, treasury and financial markets, and from consulting firms Roland Berger, Kea & Partners, Gemini Consulting and KPMG.

Ingmar Hoerr, co-founder and chief executive officer of CureVac, said: "Adding an executive with Pierre's financial and transactional expertise, as well as his global markets experience, is a key accomplishment for CureVac as the company prepares for multiple near-term corporate and clinical milestones that have the potential to significantly contribute to its leadership position in the field of mRNA."

14th October 2016

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Frontera Group

Welcome to Frontera Group, where our agencies immerse you in the world of the patient...

Latest intelligence

The ALS patient journey
Nick Goldup is the Director of Care Improvement at the Motor Neuron Disease Association (MNDA). Here, he offers his insights into the journey for patients with ALS and explores the...
Equipping your medical affairs teams with solutions to navigate the healthcare landscape
Dr Tyler Ray, OPEN Health Medical Communications...
Protein degraders
Can protein degraders unlock ‘undruggable’ drug targets?
Exploring a new and exciting area of small-molecule drug discovery...

Infographics